November 30, 2016 - By Clifton Ray · 0 Comments
Nov 30 is a negative day so far for SPDR S&P Biotech ETF (NYSEARCA:XBI) as the ETF is active during the day after losing 2.12% to hit $63.2 per share. The exchange traded fund has 3.21B net assets and 3.02% volatility this month.
Over the course of the day 673,935 shares traded hands, as compared to an average volume of 6.63M over the last 30 days for SPDR S&P Biotech ETF (NYSEARCA:XBI).
The ETF is -9.86% of its 52-Week High and 50.31% of its low, and is currently having ATR of 2.22. This year’s performance is -5.45% while this quarter’s performance is 4.56%.
The ETF’s YTD performance is -19.81%, the 1 year is -15.34% and the 3 year is 13.06%.
The ETF’s average P/E ratio is 19.64, the price to book is 2.76, the price to sales is 7.08 and the price to cashflow is 10.94. It was started on 02/06/2006. The fund’s top holdings are: Sarepta Therapeutics Inc. for 3.86% of assets, TESARO Inc. for 3.53%, Incyte Corporation for 2.94%, Alexion Pharmaceuticals Inc. for 2.80%, United Therapeutics Corporation for 2.68%, Celgene Corporation for 2.62%, Gilead Sciences Inc. for 2.53%, Biogen Inc. for 2.53%, Regeneron Pharmaceuticals Inc. for 2.40%, Ionis Pharmaceuticals Inc. for 2.40%. The ETF sector weights are: Healthcare 100.00%. The ETF currently as 0.51% yield.
More notable recent SPDR S&P Biotech (ETF) (NYSEARCA:XBI) news were published by: Bloomberg.com which released: “Options Insight: How to Trade the SPDR S&P Biotech ETF” on October 06, 2016, also Investorplace.com with their article: “Buy the SPDR S&P Biotech (ETF) (XBI) TODAY â€“ Here’s Why” published on November 09, 2016, Benzinga.com published: “Dan Nathan’s SPDR S&P Biotech ETF Trade” on October 24, 2016. More interesting news about SPDR S&P Biotech (ETF) (NYSEARCA:XBI) were released by: Investorplace.com and their article: “Try the SPDR S&P Biotech (ETF) (XBI) if You’re Bullish on the Biotech Pause” published on November 16, 2016 as well as Investorplace.com‘s news article titled: “SPDR S&P Biotech (ETF) (XBI): Embrace the Biotech Bulls’ Return” with publication date: August 11, 2016.
SPDR S&P Biotech ETF seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The ETF has a market cap of $3.21 billion. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. It has a 3.47 P/E ratio. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Clifton Ray